Item 2.02 Results of Operations and Financial Condition.

On January 9, 2023, Mirati Therapeutics, Inc. (the "Company") presented a slide presentation containing, among other things, the Company's unaudited cash, cash equivalents and short-term investments as of December 31, 2022, during the 41st Annual J.P. Morgan Healthcare Conference at 9:00 AM PT/12:00 PM CT. A copy of the slide presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On January 9, 2023, the Company presented a slide presentation further containing, among other things, updates to the Company's business during the 41st Annual J.P. Morgan Healthcare Conference at 9:00 AM PT/12:00 PM CT. A copy of the slide presentation is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
  No.       Description

99.1          Slide presentation.

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses